Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Food and Drug Administration

          - [Docket No. 2005N-0375]

# AGENCY:

Food and Drug Administration, HHS.

# ACTION:

Notice of public meeting.

# SUMMARY:

The Food and Drug Administration (FDA) is announcing the following public meeting: A New Direction for FDA's Radiological Health Program. The topics of discussion are the agency's activities to implement its radiological health program (the program).

# DATES:

The public meeting will be held on October 31 and November 1, 2005, from 8:30 a.m. to 5 p.m. The agency is requiring registration by October 17, 2005.

All parties wishing to make a presentation or to speak on an issue specific to the topics of the meeting should indicate their intent, the topics to be addressed, and provide an abstract of their comments to be presented by October 17, 2005. FDA will limit the time for presentations to the public comment periods; the number of parties requesting to participate will determine the amount of time allotted to each presentation.

# ADDRESSES:

The public meeting will be held at the Hilton Washington DC North/Gaithersburg, 620 Perry Pkwy., Gaithersburg, MD 20877.

                        Submit written requests to make an oral presentation to Kaye Chesemore (see                         **FOR FURTHER INFORMATION CONTACT**                        ). Include your name, title, firm or organization name (if representing such), address, telephone, and fax number with your request. All requests and presentation materials should include the docket number found in brackets in the heading of this document. Submit all requests for suggestions and recommendations to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.                    

# FOR FURTHER INFORMATION CONTACT:

                        Kaye Chesemore, Center for Devices and Radiological Health (HFZ-240), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 301-594-3309, FAX: 301-594-3306, e-mail:                         *kfc@cdrh.fda.gov*.                    

# SUPPLEMENTARY INFORMATION:

## I. Background

                    In May 2004, FDA's Center for Devices and Radiological Health (CDRH) began an effort to examine how the program could best adapt to current public health needs. This effort culminated in a report that outlines key elements of the program and states how the new direction will impact the most pressing public health problems in the radiological health area. A copy of the report is available on CDRH's Web site at                     *http://www.fda.gov/​cdrh/​radhlth/​initiative.html*.                

The agency has determined that it must shift the focus of resources to the products and procedures with the highest risks to the public, including those that affect the greatest number of people or present the potential for the greatest harm.

The benefits that FDA expects from this focus are that the new program will:

(1) Align CDRH efforts with current and evolving public health needs,

(2) Expand focus on patient and consumer protection,

(3) Allow for a more targeted approach to FDA's programs and activities,
      ( print page 55910)    
(4) Increase information dissemination and training, and

(5) Improve coordination across the radiological health community.

## II. Agenda

On October 31, 2005, FDA is providing the opportunity for a number of stakeholder organizations to discuss how they can assist FDA in implementing the program and in addressing important public health problems. FDA and its stakeholders will discuss the following aspects of the radiological health plan overview:
    - Standards—Discussion will consider the following topics: Increased reliance by FDA on consensus radiation safety performance standards, the role of national and international standards, and the role of State regulations in assuring product safety and proper use.
    - Monitoring the Use of Radiation—Discussion will consider the following topics: The shift of CDRH's focus from products to users, patients, and consumers; adverse event reporting; State program roles in ensuring appropriate use of radiation; facility quality assurance programs; and the establishment of a voluntary patient radiation dose reporting system for diagnostic imaging procedures that use ionizing radiation. This system could be used to monitor national exposure trends and provide a basis for establishing diagnostic reference levels of patient dose for use in facility quality improvement programs.
    - Monitoring the Industry—Discussion will consider the following topics: The shift of FDA emphasis from testing products, to inspecting manufacturers to assure quality manufacturing and products; the reduction of reporting requirements; and the development of electronic reporting methods.
    - Education—Discussion will consider education and training for manufacturers, regulators, and users.

On November 1, 2005, FDA will hold concurrent discussion sessions throughout the day on the Standards, Monitoring, and Education topics to provide further opportunity for stakeholder comment and discussion.

FDA will provide an opportunity for comment during the public comment period for individuals and/or organizations on October 31, 2005. In addition, the agency will provide an opportunity to present individual viewpoints during the concurrent discussion sessions on November 1, 2005. FDA reserves the right to limit the time of speakers during the public comment periods.

## III. Registration

                    Participants must register for the meeting by October 17, 2005. Acceptance will be on a first-come, first-served basis. There will be no onsite registration and unregistered participants will not be added to the program. Please register online at                     *http://www.fda.gov/​cdrh/​meetings/​120303.html*. Persons without Internet access may register for the onsite meeting by calling 301-594-3309 by October 17, 2005.                

If you need special accommodations due to a disability, please fax information regarding those needs to Kaye Chesemore at 301-594-3306, at least 7 days in advance of the meeting.

## IV. Request for Suggestions, Recommendations, and Materials

                    FDA is particularly interested in receiving suggestions from stakeholders related to the topics listed previously in this document. Send suggestions or recommendations to the Division of Dockets Management (see                     **ADDRESSES**                    ).                

                    FDA will place an additional copy of any material it receives in the docket for this document (2005N-0375). Suggestions, recommendations, and materials may be seen at the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday (see                     **ADDRESSES**                    ).                

## V. Transcripts

                    Following the meeting, transcripts will be available for review at the Division of Dockets Management (see                     **ADDRESSES**                    ).                

Dated: September 19, 2005.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. 05-19077 Filed 9-20-05; 3:31 pm]

BILLING CODE 4160-01-S